The logistic regression model combining the five mRNA biomarkers (CCNI, EGFR, FGF19, FRS2, and GREB1) can distinguish patients with lung cancer from normal controls (area under the receiver operating characteristic curve [AUC-ROC] = 0.925; sensitivity = 93.75%; specificity = 82.81%). This evidence concerns the gene FRS2 and lung carcinoma.